Gene Editing with CRISPR Training Workshop

Published on :

This remote rigorous three-day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. laboratory introduction to CRISPR toolkit. Taught by active [….]

Exosomes: Principles, Methods and Applications Training Workshop

Published on :

This four day live remote program is ideal for research and translational biology scientists who are looking for a balanced theoretical and introduction to isolation, quantitation, analysis and engineering of [….]

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

Published on :

Arcellx, a privately held clinical- stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022. In addition, the funding will support initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from Arcellx’s uniquely controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.

5 Questions with Raj Vora, PE, Life Sciences Core Market Leader, DPR Construction

Published on :

Raj Vora is a Life Sciences Core Market Leader, Responsible for business growth, technical expertise, and account management of the DPR Construction’s life sciences portfolio in the region through project and customer development or project-specific roles. Focused on cGMP manufacturing facilities primarily in the cell and gene therapy market and involved in lab, containment, and other research projects.

CARB-X is Funding Baltimore’s Novel Microdevices to Develop a Rapid and Portable Diagnostic for STDs Including Antibiotic-Resistant Infections

Published on :

CARB-X is funding Novel Microdevices to develop a rapid and portable diagnostic for sexually transmitted diseases including antibiotic-resistant infections  New portable battery-powered diagnostic is designed to be easy-to-use in any setting around [….]

Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma

Published on :

Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma.